Early evidence generation for European HTA is an important consideration for Asia-Pacific (APAC) pharmaceutical manufacturers planning to launch their products in Europe. When planning evidence generation, manufacturers need to look beyond regulatory requirements and consider not only market access and HTA expectations, but also how these differ across geographies.
Examples of US and European pharmaceutical manufacturers launching in Asia-Pacific (APAC) markets have highlighted how evidence-generation strategies that are not tailored to local requirements, such as insufficient recruitment of patients from relevant populations or the selection of inappropriate comparators, can contribute to suboptimal market-access outcomes.
Our previous research, presented at ISPOR APAC, explored how EU-focused evidence planning may contribute to unfavourable HTA outcomes in APAC markets. We hypothesise that the reverse may also be true, with APAC manufacturers facing similar challenges when undergoing HTA in Europe. By exploring both cases, we aim to identify the key challenges for manufacturers planning global launches and how early evidence planning could help mitigate market access risks.
Drawing on HTA precedents from Europe and APAC, this session will explore:
• What evidence gaps contribute to sub-optimal HTA outcomes across European and APAC markets
• Key drivers of sub-optimal HTA outcomes for US/EU manufacturers launching in APAC versus APAC manufacturers launching in Europe
• What these findings mean for manufacturers planning global launches and how early, globally informed PICOS planning could help mitigate market access risks